SCHEMBL12875696

SCHEMBL12875696

CCOC(=O)c1cnn(Cc2nc(-c3cccc(C)c3)cs2)c1C

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
KDM4E B2RXH2 7/20 0.50
HPGD P15428 6/20 0.50
L3MBTL1 Q9Y468 5/20 0.50
ALDH1A1 P00352 5/20 0.50
MAPT P10636 4/20 0.50
GAA P10253 3/20 0.50
MEN1 O00255 2/20 0.50
CYP1A2 P05177 2/20 0.50
CYP2C9 P11712 2/20 0.50
CYP2C19 P33261 2/20 0.50
TDP1 Q9NUW8 2/20 0.46
AKT1 P31749 1/20 0.44
CNKSR1 Q969H4 1/20 0.44
JAK2 O60674 1/20 0.43
JAK3 P52333 1/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 3/20 0.43
HSD17B10 Q99714 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12875697 0.88 SIRT5 (0.44) KMT2AKDM4EHPGDL3MBTL1ALDH1A1
SCHEMBL12875535 0.82 KDM4E (0.66) KMT2ASMN1; SMN2KDM4EHPGDL3MBTL1
SCHEMBL12875688 0.81 L3MBTL1 (0.47) KMT2ASMN1; SMN2KDM4EHPGDL3MBTL1
SCHEMBL12875680 0.80 L3MBTL1 (0.44) KMT2ASMN1; SMN2KDM4EHPGDL3MBTL1
SCHEMBL1199217 0.80 KDM4E (0.61) KMT2AKDM4EHPGDL3MBTL1ALDH1A1
SCHEMBL1198797 0.79 KDM4E (0.53) KMT2AKDM4EHPGDL3MBTL1ALDH1A1
SCHEMBL12876343 0.79 NPC1 (0.41) KMT2AKDM4EHPGDL3MBTL1ALDH1A1
SCHEMBL1198469 0.77 KDM4E (0.44) KMT2AKDM4EHPGDL3MBTL1ALDH1A1
SCHEMBL12876353 0.77 NFE2L2 (0.42) KDM4EALDH1A1AKT1GRIN2BITGB3
SCHEMBL12890154 0.77 CNKSR1 (0.39) KMT2AKDM4EHPGDL3MBTL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A KMT2A 3197/4885SMN1; SMN2 2057/4885KDM4E 1877/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.